Carna Biosciences, Inc.

Tokyo Stock Exchange 4572.T

Carna Biosciences, Inc. Return on Equity (ROE) for the year ending December 31, 2023: -29.73%

Carna Biosciences, Inc. Return on Equity (ROE) is -29.73% for the year ending December 31, 2023, a 19.76% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Carna Biosciences, Inc. Return on Equity (ROE) for the year ending December 31, 2022 was -37.06%, a -199.21% change year over year.
Carna Biosciences, Inc. Return on Equity (ROE) for the year ending December 31, 2021 was -12.38%, a 57.37% change year over year.
Carna Biosciences, Inc. Return on Equity (ROE) for the year ending December 31, 2020 was -29.05%, a -235.17% change year over year.
Carna Biosciences, Inc. Return on Equity (ROE) for the year ending December 31, 2019 was 21.49%, a 115.76% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Tokyo Stock Exchange: 4572.T

Carna Biosciences, Inc.

CEO	Dr. Kohichiro Yoshino Ph.D.
IPO Date	March 25, 2008
Location	Japan
Headquarters	BMA, 1-5-5 Minatojima-Minamimachi
Employees	67
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.

Key trends

Past 5 years